{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:23:31Z","timestamp":1770798211793,"version":"3.50.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2019"],"award-info":[{"award-number":["UID\/Multi\/04349\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-QUI\/1554\/2020"],"award-info":[{"award-number":["PTDC\/MED-QUI\/1554\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.07119.BD"],"award-info":[{"award-number":["2020.07119.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PRT\/BD\/154612\/2023"],"award-info":[{"award-number":["PRT\/BD\/154612\/2023"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PRT\/BD\/154625\/2023"],"award-info":[{"award-number":["PRT\/BD\/154625\/2023"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101008571"],"award-info":[{"award-number":["101008571"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-025-00339-6","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:34:21Z","timestamp":1744364061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161"],"prefix":"10.1186","volume":"10","author":[{"given":"Joana F.","family":"Santos","sequence":"first","affiliation":[]},{"given":"Camille Van","family":"Laere","sequence":"additional","affiliation":[]},{"given":"Catarina D.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Irwin","family":"Cassells","sequence":"additional","affiliation":[]},{"given":"C\u00e9lia","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Raposinho","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Belchior","sequence":"additional","affiliation":[]},{"given":"Catarina I. G.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Cawthorne","sequence":"additional","affiliation":[]},{"given":"Maarten","family":"Ooms","sequence":"additional","affiliation":[]},{"given":"Michiel Van de","family":"Voorde","sequence":"additional","affiliation":[]},{"given":"Frederik","family":"Cleeren","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-0913","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Paulo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"339_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1021\/bc060156+","volume":"17","author":"C Antczak","year":"2006","unstructured":"Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA. Influence of the linker on the biodistribution and catabolism of Actinium-225 Self-Immolative Tumor-Targeted isotope generators. Bioconjug Chem. 2006;17:1551\u201360.","journal-title":"Bioconjug Chem"},{"key":"339_CR13","doi-asserted-by":"publisher","first-page":"11047","DOI":"10.3390\/ijms222011047","volume":"22","author":"D Averbeck","year":"2021","unstructured":"Averbeck D, Rodriguez-Lafrasse C. Role of mitochondria in radiation responses: epigenetic, metabolic, and signaling impacts. Int J Mol Sci. 2021;22:11047.","journal-title":"Int J Mol Sci"},{"key":"339_CR26","doi-asserted-by":"publisher","first-page":"7114","DOI":"10.1038\/s41598-021-86551-1","volume":"11","author":"S Boinapally","year":"2021","unstructured":"Boinapally S, Ahn H-H, Cheng B, Brummet M, Nam H, Gabrielson KL, et al. A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile. Sci Rep. 2021;11:7114.","journal-title":"Sci Rep"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","volume":"64","author":"J Bolcaen","year":"2023","unstructured":"Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, et al. Marshalling the potential of Auger electron radiopharmaceutical therapy. J Nucl Med. 2023;64:1344\u201351.","journal-title":"J Nucl Med"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, et al. Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"339_CR20","doi-asserted-by":"publisher","first-page":"675122","DOI":"10.3389\/fmed.2021.675122","volume":"8","author":"I Cassells","year":"2021","unstructured":"Cassells I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T, et al. Radiolabeling of human serum albumin with Terbium-161 using mild conditions and evaluation of in vivo stability. Front Med. 2021;8:675122.","journal-title":"Front Med"},{"key":"339_CR11","doi-asserted-by":"publisher","first-page":"110140","DOI":"10.1016\/j.apradiso.2022.110140","volume":"182","author":"SM Collins","year":"2022","unstructured":"Collins SM, Gilligan C, Pierson B, Ramirez N, Goodwin M, Pearce AK, et al. Determination of the 161Tb half-life. Appl Radiat Isot. 2022;182:110140.","journal-title":"Appl Radiat Isot"},{"key":"339_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2967\/jnumed.122.265268","volume":"64","author":"C Favaretto","year":"2023","unstructured":"Favaretto C, Grundler PV, Talip Z, Landolt S, Sepini L, K\u00f6ster U, et al. 161Tb-DOTATOC production using a fully automated disposable cassette system: A first step toward the introduction of 161 Tb into the clinic. J Nucl Med. 2023;64:1138\u201344.","journal-title":"J Nucl Med"},{"key":"339_CR15","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.3390\/ijms23137238","volume":"23","author":"C Fernandes","year":"2022","unstructured":"Fernandes C, Palma E, Silva F, Belchior A, Pinto CIG, Guerreiro JF, et al. Searching for a paradigm shift in Auger-Electron cancer therapy with Tumor-Specific radiopeptides targeting the mitochondria and\/or the cell nucleus. Int J Mol Sci. 2022;23:7238.","journal-title":"Int J Mol Sci"},{"key":"339_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/molecules26020441","volume":"26","author":"D Figueiredo","year":"2021","unstructured":"Figueiredo D, Fernandes C, Silva F, Palma E, Raposinho P, Belchior A, et al. Synthesis and biological evaluation of 99mTc(I) Tricarbonyl complexes Dual-Targeted at tumoral mitochondria. Molecules. 2021;26:441.","journal-title":"Molecules"},{"key":"339_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2967\/jnumed.123.266233","volume":"65","author":"N Holzleitner","year":"2024","unstructured":"Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al. Preclinical evaluation of Gastrin-Releasing peptide receptor antagonists labeled with 161 Tb and 177 Lu: A comparative study. J Nucl Med. 2024;65:481\u20134.","journal-title":"J Nucl Med"},{"key":"339_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2967\/jnumed.123.265509","volume":"64","author":"A Larouze","year":"2023","unstructured":"Larouze A, Alcocer-\u00c1vila M, Morgat C, Champion C, Hindi\u00e9 E. Membrane and nuclear absorbed doses from 177Lu and 161Tb in tumor clusters: effect of cellular heterogeneity and potential benefit of dual Targeting\u2014A Monte Carlo study. J Nucl Med. 2023;64:1619\u201324.","journal-title":"J Nucl Med"},{"key":"339_CR25","doi-asserted-by":"publisher","first-page":"17123","DOI":"10.1021\/acs.jmedchem.1c01157","volume":"64","author":"AE Machulkin","year":"2021","unstructured":"Machulkin AE, Uspenskaya AA, Zyk NU, Nimenko EA, Ber AP, Petrov SA, et al. Synthesis, characterization, and preclinical evaluation of a Small-Molecule Prostate-Specific membrane Antigen-Targeted monomethyl auristatin E conjugate. J Med Chem. 2021;64:17123\u201345.","journal-title":"J Med Chem"},{"key":"339_CR24","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.2967\/jnumed.119.226787","volume":"60","author":"SP McCluskey","year":"2019","unstructured":"McCluskey SP, Haslop A, Coello C, Gunn RN, Tate EW, Southworth R, et al. Imaging of Chemotherapy-Induced acute cardiotoxicity with 18F-Labeled lipophilic cations. J Nucl Med. 2019;60:1750\u20136.","journal-title":"J Nucl Med"},{"key":"339_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"339_CR23","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","volume":"58","author":"GP Nicolas","year":"2017","unstructured":"Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-Labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the mass effect. J Nucl Med. 2017;58:1435\u201341.","journal-title":"J Nucl Med"},{"key":"339_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fchem.2020.00783","volume":"8","author":"L Pala","year":"2020","unstructured":"Pala L, Senn HM, Caldwell ST, Prime TA, Warrington S, Bright TP, et al. Enhancing the mitochondrial uptake of phosphonium cations by carboxylic acid incorporation. Front Chem. 2020;8:783.","journal-title":"Front Chem"},{"key":"339_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00259-019-04584-1","volume":"47","author":"S Rasul","year":"2020","unstructured":"Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubm\u00fcller B, Kramer G, et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47:713\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"339_CR21","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA Double-stranded breaks induce histone H2AX phosphorylation on Serine 139. J Biol Chem. 1998;273:5858\u201368.","journal-title":"J Biol Chem"},{"key":"339_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/pharmaceutics11110560","volume":"11","author":"EAM Ruigrok","year":"2019","unstructured":"Ruigrok EAM, Van Weerden WM, Nonnekens J, De Jong M. The future of PSMA-Targeted radionuclide therapy: an overview of recent preclinical research. Pharmaceutics. 2019;11:560.","journal-title":"Pharmaceutics"},{"key":"339_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1021\/acs.molpharmaceut.3c00787","volume":"21","author":"JF Santos","year":"2024","unstructured":"Santos JF, Braz MT, Raposinho P, Cleeren F, Cassells I, Leekens S, et al. Synthesis and preclinical evaluation of PSMA-Targeted 111In-Radioconjugates containing a Mitochondria-Tropic triphenylphosphonium carrier. Mol Pharm. 2024;21:216\u201333.","journal-title":"Mol Pharm"},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2967\/jnumed.124.267873","volume":"65","author":"K Spoormans","year":"2024","unstructured":"Spoormans K, Struelens L, Vermeulen K, De Saint-Hubert M, Koole M, Crabb\u00e9 M. The emission of internal conversion electrons rather than Auger electrons increased the Nucleus-Absorbed dose for 161Tb compared with 177Lu with a higher dose response for [161Tb]Tb-DOTA-LM3 than for [161Tb]Tb-DOTATATE. J Nucl Med. 2024;65:1619\u201325.","journal-title":"J Nucl Med"},{"key":"339_CR8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, K\u00f6ster U, et al. Albumin-Binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331.","journal-title":"J Nucl Med"},{"key":"339_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.7150\/thno.92775","volume":"14","author":"C Van Laere","year":"2024","unstructured":"Van Laere C, Koole M, Deroose CM, De Voorde MV, Baete K, Cocolios TE, et al. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside. Theranostics. 2024;14:1720\u201343.","journal-title":"Theranostics"},{"key":"339_CR19","doi-asserted-by":"crossref","unstructured":"Xie Z, Zhao M, Yan C, Kong W, Lan F, Narengaowa, et al. Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways. Cell Death Dis. 2023;14:255.","DOI":"10.1038\/s41419-023-05786-0"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","volume":"117","author":"J Zielonka","year":"2017","unstructured":"Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, et al. Mitochondria-Targeted Triphenylphosphonium-Based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017;117:10043\u2013120.","journal-title":"Chem Rev"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00339-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00339-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00339-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:34:24Z","timestamp":1744364064000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00339-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00339-6","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In vivo experiments were approved by the KU Leuven ethical review board and conducted in accordance with the Belgian and EU law of animal protection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}